Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
Total Valuation
Rhythm Pharmaceuticals has a market cap or net worth of $6.39B. The enterprise value is $6.58B.
Market Cap$6.39B
Enterprise Value$6.58B
Share Statistics
Rhythm Pharmaceuticals has 68,285,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding68,285,040
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Rhythm Pharmaceuticals’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -50.11%.
Return on Equity (ROE)-1.41
Return on Assets (ROA)-0.41
Return on Invested Capital (ROIC)-50.11%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee670.52K
Profits Per Employee-694.48K
Employee Count283
Asset Turnover0.39
Inventory Turnover0.76
Valuation Ratios
The current PE Ratio of Rhythm Pharmaceuticals is ―. Rhythm Pharmaceuticals’s PEG ratio is 1.25.
PE Ratio―
PS Ratio36.66
PB Ratio50.02
Price to Fair Value50.02
Price to FCF-59.64
Price to Operating Cash Flow-54.07
PEG Ratio1.25
Income Statement
In the last 12 months, Rhythm Pharmaceuticals had revenue of 189.76M and earned -196.54M in profits. Earnings per share was -3.11.
Revenue189.76M
Gross Profit170.26M
Operating Income-192.02M
Pretax Income-196.04M
Net Income-196.54M
EBITDA-174.12M
Earnings Per Share (EPS)-3.11
Cash Flow
In the last 12 months, operating cash flow was -115.67M and capital expenditures -953.00K, giving a free cash flow of -116.63M billion.
Operating Cash Flow-115.67M
Free Cash Flow-116.63M
Free Cash Flow per Share-1.71
Dividends & Yields
Rhythm Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change92.59%
50-Day Moving Average102.46
200-Day Moving Average94.81
Relative Strength Index (RSI)42.31
Average Volume (3m)724.45K
Important Dates
Rhythm Pharmaceuticals upcoming earnings date is May 5, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 5, 2026
Ex-Dividend Date―
Financial Position
Rhythm Pharmaceuticals as a current ratio of 4.41, with Debt / Equity ratio of 177.23%
Current Ratio4.41
Quick Ratio4.16
Debt to Market Cap0.03
Net Debt to EBITDA-1.10
Interest Coverage Ratio-9.33
Taxes
In the past 12 months, Rhythm Pharmaceuticals has paid 497.00K in taxes.
Income Tax497.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Rhythm Pharmaceuticals EV to EBITDA ratio is -41.05, with an EV/FCF ratio of -61.29.
EV to Sales37.67
EV to EBITDA-41.05
EV to Free Cash Flow-61.29
EV to Operating Cash Flow-61.79
Balance Sheet
Rhythm Pharmaceuticals has $388.95M in cash and marketable securities with $246.47M in debt, giving a net cash position of $142.48M billion.
Cash & Marketable Securities$388.95M
Total Debt$246.47M
Net Cash$142.48M
Net Cash Per Share$2.09
Tangible Book Value Per Share$2.06
Margins
Gross margin is 89.73%, with operating margin of -101.19%, and net profit margin of -103.57%.
Gross Margin89.73%
Operating Margin-101.19%
Pretax Margin-103.31%
Net Profit Margin-103.57%
EBITDA Margin-91.76%
EBIT Margin-92.47%
Analyst Forecast
The average price target for Rhythm Pharmaceuticals is $140.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$140.29
Price Target Upside50.01% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast54.92%
EPS Growth Forecast28.47%